Newborn jaundice treatment market seen reaching $3.49 billion by 2030

The newborn jaundice treatment market is projected to grow from $2.71 billion in 2025 to $3.49 billion by 2030, driven by wider use of LED phototherapy, earlier screening and expanding neonatal care. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Newborn jaundice treatment is tied to early detection and management of elevated bilirubin in infants, which helps prevent serious complications and supports healthy neonatal development. - The market's growth points to broader demand for neonatal care tools, especially in settings expanding screening, phototherapy access and non-invasive monitoring. - Rising birth rates add to the number of newborns needing jaundice management.

What happened: - The Business Research Company said the newborn jaundice treatment market is expected to rise from $2.71 billion in 2025 to $2.84 billion in 2026. - The company forecasts the market will reach $3.49 billion by 2030, reflecting a 5.3% CAGR. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period.

The details: - Earlier growth was driven by the high global prevalence of neonatal jaundice. - Limited access to advanced phototherapy devices in resource-constrained areas supported continued demand for older systems. - Dependence on traditional fluorescent lamp systems remained a market factor. - Late diagnosis of hyperbilirubinemia and the lack of uniform neonatal screening protocols also contributed to demand. - Growth through 2030 is expected to come from wider adoption of LED-based phototherapy. - Early neonatal screening programs are expected to support market expansion. - Home-based newborn care options are becoming more popular. - Non-invasive bilirubin monitoring methods are improving. - Neonatal intensive care facilities are expanding globally. - Emerging products include LED intensive phototherapy systems for faster bilirubin reduction. - Fiber-optic blanket phototherapy is gaining attention because it allows continuous treatment with less discomfort for infants. - Smart bilirubin monitors can adjust phototherapy in real time. - Portable homecare phototherapy units support earlier discharge. - Dual-surface phototherapy devices are designed to improve treatment efficiency in neonatal intensive care environments. - The market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, and the Middle East and Africa. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The company offered a free sample report and a full report through its website: Download the free sample and View the full report.

Between the lines: - The forecast suggests the market is moving from basic treatment delivery toward more portable, automated and home-friendly systems. - The emphasis on screening and non-invasive monitoring indicates a shift toward earlier intervention rather than treatment after symptoms become severe. - The regional outlook suggests mature demand in North America and faster expansion potential in developing neonatal care markets in Asia-Pacific.

What's next: - LED phototherapy, portable homecare devices and real-time bilirubin monitoring are likely to shape product development through 2030. - Market growth will depend on whether health systems expand screening, improve access to phototherapy and increase neonatal intensive care capacity. - Rising births and broader adoption of neonatal care technologies are expected to keep demand elevated.

The bottom line: - Newborn jaundice treatment is forecast to remain a steady growth market through 2030, with technology upgrades and broader newborn care access driving the next phase of expansion.